# Australia's Synedica peptide warning

Canonical: https://europeanpeptideshop.com/blog/synedica-tga-warning-australia-tb-500/

Explore the catalogue and research library. Ordering and shipping have not opened yet.

Research news · 8 November 2026 · 2 min read · By [European Peptide Shop](https://europeanpeptideshop.com/about/)

### On this page

Australia's Therapeutic Goods Administration (TGA) issued a warning on 6 November 2026 about Synedica injectable products after testing found they did not contain what their labels claimed. The Herald Sun reported the finding the same day.

## Which products were tested?

Three products : Synedica BPC 157 & TB 500 10 mg, Synedica KLOW 80 mg and Synedica BARBIE KLOW 100 mg : contained no detectable TB-500 despite claiming to. Products also labelled as containing retatrutide, an unapproved GLP-1 drug still in clinical trials, held less than the stated 10 mg. The amount varied significantly between individual pens tested.

## What risk did the TGA identify?

TGA chief medical adviser Professor Robyn Langham said: uncertain contents and the possibility of severe allergic reactions were central concerns.

TGA head Chris Bedford called the growing unlawful supply and promotion of unapproved peptides "a serious concern" and said the regulator would work with law enforcement to disrupt it. The products were seized in a NSW police operation.

## Why is this relevant in the UK?

The UK's MHRA has [investigated peptide clinics](https://europeanpeptideshop.com/blog/peptide-clinics-uk-mhra/) and [raided premises in Birmingham](https://europeanpeptideshop.com/blog/mhra-birmingham-raid-fake-pens/) for similar products. The [ASA Pulse Report](https://europeanpeptideshop.com/blog/research-peptides-uk-asa-advertising-report/) rated no sampled research peptide ad as low compliance risk. The TGA finding adds evidence that unlabelled injectable products carry unknown contents and risk.

## Scope for European readers

This is a dated account of the research or policy described in the linked sources. The stated jurisdiction, study product and population matter. A US or UK announcement does not establish authorisation or availability across Europe. Nothing in this report establishes results for an EPS catalogue material. Read the [research-use statement](https://europeanpeptideshop.com/research-use/) for the storefront's scope.

## Laboratory research only

Materials listed on this site are supplied for in-vitro laboratory research and are not for use in or on humans or animals. They are not medicines. This article summarises published work and gives no dosing, administration, treatment or in-vivo guidance. Findings from a study apply to the material and conditions of that study, and they say nothing about any product listed here.

## References

- [Herald Sun, 6 November 2026](https://www.heraldsun.com.au/health/wellbeing/cosmetic-health/serious-risk-lab-tests-on-popular-synedica-peptides-revealed/news-story/e82e7b1ba9606a5dcbb170f50f4a7bac)

## More articles

Research news · 3 min read

## [The FDA's RonanRx GLP-1 warning](https://europeanpeptideshop.com/blog/fda-ronanrx-compounded-glp1-warning/)

Read the FDA’s RonanRx warning in context: compounded semaglutide and tirzepatide, approval claims, manufacturer identity and product-origin language.

8 November 2026

Research news · 3 min read

## [Avexitide and the LUCIDITY trial](https://europeanpeptideshop.com/blog/avexitide-glp-1-antagonist-lucidity/)

Why does avexitide block GLP-1? Explore post-bariatric hypoglycemia, LUCIDITY results and Amylyx’s November 2026 FDA-filing and conference plans.

8 November 2026

Research news · 3 min read

## [BPC-157: UK and US regulatory context](https://europeanpeptideshop.com/blog/is-bpc-157-legal-in-the-uk/)

The October 2026 US peptide policy is not UK authorisation. Read the MHRA classification framework and why research-use wording cannot settle a product's.

8 November 2026